相关实验视频
Updated: Dec 24, 2025

09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
3.3K
与XA因子抑制剂相关的内出血:多中心观察队列接受前列红素复合度的结果
Nicholas G Panos1, Aaron M Cook2, Sayona John3
1Department of Pharmacy (N.G.P.), Rush University Medical Center, Chicago, IL.
Circulation
|April 9, 2020
概括
在服用XA因子抑制剂的患者中,血复合物 (PCC) 有效控制了内出血 (ICH),表现为高血静率和低血栓形成风险. 建议对与XA抑制剂相关的ICH进行进一步的随机试验.
科学领域:
- 神经学
- 血液学
- 药理学
背景情况:
- 口服的XA抑制剂被广泛使用,这引发了有关内出血 (ICH) 的担忧.
- 目前的指导方针建议针对与XA因子抑制剂相关的ICH使用前热血素复合缩剂 (PCC),但证据基于有限的患者数据.
- 这项研究解决了对XA因子抑制剂相关的ICH中PCC的较大队列数据的需求.
研究的目的:
- 在XA因子抑制剂相关的内出血 (ICH) 患者中评估前血复合物 (PCC) 的安全性和有效性.
- 在该患者群体中评估血静效和血栓事件的发生.
主要方法:
- 一项多中心,回顾性,观察性队列研究包括用PCC治疗的阿皮克萨班或里瓦罗克萨班相关的ICH患者.
- 安全性分析侧重于血栓事件,而血静疗效则使用基于随访成像的修改后的Sarode标准进行评估.
- 住院死亡率,住院时间和输液反应是次要结果.
主要成果:
- 在433名患者中,81. 8%的患者获得了优异或良好的血静.
- 在3. 8%的患者中,总共发生了26起血栓事件,大多数事件发生在PCC给药后14天内.
- 住院死亡率为19. 0%,平均ICU和住院时间分别为2. 0和6. 0天.
结论:
- 在与XA抑制剂相关的ICH患者中,血组复合缩剂 (PCC) 显示出高血静效 (81. 8%) 和低血栓形成率 (3. 8%).
- 这些发现支持PCC在临床环境中的使用,但强调需要进一步研究.
- 随机对照试验对于确定PCCs对因子Xa抑制剂相关的ICH的临床疗效至关重要.
相关概念视频
Venous Thrombosis III: Interprofessional Care
217
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
217
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Extrinsic and Intrinsic Pathways of Hemostasis
11.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.4K
Disorders of Hemostasis
1.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.8K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
219
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
219

